This article was originally published in The Gray Sheet
Board authorizes the repurchase of up to 1 mil. shares of common stock "subject to certain conditions and limitations," the firm reports. As of March 26, Spacelabs had 11.3 mil. shares outstanding. "Repurchase will occur in the open market from time to time and the repurchased shares will be used in conjunction with the company's stock option, stock purchase and other benefit plans"....
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.